

Claims

1. Composition comprising
 - (i) Bacterial Ghosts,
 - (ii) optionally an active agent and
 - (iii) a pharmaceutically acceptable carrier and/or excipientfor use in the treatment or prevention of cancer.
2. Composition comprising, in particular consisting of
 - (i) Bacterial Ghosts, and
 - (ii) a pharmaceutically acceptable carrier and/or excipientfor use in the treatment or prevention of cancer.
3. Composition comprising, in particular consisting of
 - (i) Bacterial Ghosts,
 - (ii) an active agent and
 - (iii) a pharmaceutically acceptable carrier and/or excipientfor use in the treatment or prevention of cancer.
4. The composition for use according to claim 3, wherein the active agent is a chemotherapeutic drug, for example doxorubicin, oxaliplatin, resveratrol, epirubicin, idarubicin, mitoxantrone, cyclophosphamide, maphosphamide, bortezomib or bleomycin.
5. The composition for use according to claim 3, wherein the active agent is a chemotherapeutic drug, preferably a platinum-based chemotherapeutic drug, in particular oxaliplatin.
6. The composition for use according to any one of claims 3 to 5, wherein the Bacterial Ghosts are mixed or loaded with the active agent, preferably wherein the active agent is immobilized within the Bacterial Ghosts.

7. The composition for use according to any one of the preceding claims, wherein the composition is administered topically, intradermally, subcutaneously, orally, rectally, vaginally, intraperitoneally, intratumorally, peritumorally, and/or by intravesical instillation.
8. The composition for use according to any one of the preceding claims, wherein the Bacterial Ghosts are derived from Gram-negative bacteria, preferably from *E. coli*, more preferably from *E. coli* Nissle 1917.
9. The composition for use according to any one of the preceding claims, wherein the Bacterial Ghosts are recombinant Bacterial Ghosts, preferably carrying one or more tumor-associated antigens.
10. The composition for use according to any one of the preceding claims, wherein the composition is for use in the treatment of residual primary tumor and/or tumor metastasis.
11. The composition for use according to any one of the preceding claims, wherein the Bacterial Ghosts are obtained from bacterial cells comprising a gene encoding a lytic protein.
12. The composition for use according to any one of the preceding claims comprising Bacterial Ghosts which have been treated with β -propiolactone.
13. The composition for use according to any one of the preceding claims comprising 2×10^{10} Bacterial Ghosts per kg body weight for the first dose and 10^{10} BGs/kg for the second and following doses.
14. The composition for use according to any one of the preceding claims, wherein the cancer is selected from bladder carcinoma, breast carcinoma, colon carcinoma, colorectal carcinoma, Head and Neck

- 34 -

5 Squamous Cell Carcinoma (HNSCC), liver carcinoma, lung carcinoma, lymphoma, melanoma, mesothelioma, monocytic and myeloid leukemia, myeloma, ovarian carcinoma, pancreas carcinoma, peritoneal carcinomatosis, renal carcinoma and/or non-melanoma skin carcinoma.

15. The composition for use according to any one of the preceding claims, wherein the composition is consisting of
- 10 (i) Bacterial Ghosts,
- (ii) optionally an active agent and
- (iii) a pharmaceutically acceptable carrier and/or excipient.